-
Electronic (PDF)
-
Site License
-
Enterprisewide
Cervical Dysplasia - Pipeline Review, H1 2012
Global Markets Direct, March 2012, Pages: 49
Cervical Dysplasia – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Cervical Dysplasia - Pipeline Review, H1 2012', provides an overview of the Cervical Dysplasia therapeutic pipeline. This report provides information on the therapeutic development for Cervical Dysplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Dysplasia. 'Cervical Dysplasia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Cervical Dysplasia.
- A review of the Cervical Dysplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cervical Dysplasia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Cervical Dysplasia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cervical Dysplasia pipeline depth and focus of Cervical Dysplasia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Cervical Dysplasia Therapeutic Products under Development, Key Players in Cervical Dysplasia Therapeutics, Cervical Dysplasia Pipeline Overview, Cervical Dysplasia Pipeline, Cervical Dysplasia Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cervical Dysplasia Overview
Therapeutics Development
An Overview of Pipeline Products for Cervical Dysplasia
Cervical Dysplasia Therapeutics under Development by Companies
Cervical Dysplasia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Cervical Dysplasia Therapeutics – Products under Development by Companies
Cervical Dysplasia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Cervical Dysplasia Therapeutics Development
Inovio Biomedical Corporation
Advaxis, Inc.
N.V. Mithra Pharmaceuticals S.A.
Cervical Dysplasia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
VGX-3100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADXS-HPV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imiquimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Curcumin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fenretinide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cidofovir Gel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SGN-00101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TA-HPV + Detox + Imiquimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cervical Dysplasia Therapeutics – Drug Profile Updates
Cervical Dysplasia Therapeutics – Discontinued Products
Cervical Dysplasia Therapeutics - Dormant Products
Cervical Dysplasia – Product Development Milestones
Featured News & Press Releases
Nov 11, 2011: FDA Removes Clinical Hold For Helix's Topical Interferon Alpha-2b Phase II/III Efficacy Trial IND Application
Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines
Oct 05, 2011: Inovio's Synthetic Vaccine For Cancer Recognized As Most Promising Research At Global Vaccine Congress
Jul 15, 2011: Inovio Demonstrates T Cell Immune Response From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine
May 09, 2011: Inovio Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine
Jan 14, 2011: Advaxis Wins Approval To Complete Dosing In First Leg Of Phase II Cervical Dysplasia Trial
Oct 21, 2010: Advaxis Completes Recruitment Of First 11 Patients In US Cervical Dysplasia Study
Sep 22, 2010: Advaxis Receives Indian Approval For Cervix Cancer Trial
May 28, 2010: Advaxis Doses First Patient In Phase II Cervical Dysplasia Trial
Apr 15, 2010: Adavaxis Opens First Trial Site In Phase II Clinical Trial Of ADXS11-001
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Cervical Dysplasia, H1 2012
Products under Development for Cervical Dysplasia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Inovio Biomedical Corporation, H1 2012
Advaxis, Inc., H1 2012
N.V. Mithra Pharmaceuticals S.A., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Cervical Dysplasia Therapeutics – Drug Profile Updates
Cervical Dysplasia Therapeutics – Discontinued Products
Cervical Dysplasia Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Cervical Dysplasia, H1 2012
Products under Development for Cervical Dysplasia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
